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 2 
Abstract 32 
Purpose: this study aimed to identify subpopulations of prostate cancer cells that are responsible for the 33 
initiation of bone metastases.  34 
Procedures: Using rapidly dividing human prostate cancer cell lines, we identified mitotically quiescent 35 
subpopulations (<1%), which we compared with the rapidly dividing populations for patterns of gene 36 
expression and for their ability to migrate to the skeletons of athymic mice. The study used 2-photon 37 
microscopy to track migration of fluorescently labeled cells and luciferase expression to determine the 38 
presence of growing bone metastases. 39 
Findings: We showed that the mitotically quiescent cells were very significantly more tumourogenic in 40 
forming bone metastases than fast growing cells (55% vs 15%) and had a unique gene expression profile. 41 
The quiescent cells were not uniquely stem-cell like, with no expression of CD133 but same level 42 
expression of other putative pURVWDWHVWHPFHOOPDUNHUV&'DQGLQWHJULQVĮȕZKHQFRPSDUHGWRWKH43 
rapidly proliferating population. In addition, mitotic quiescence was associated with very high levels of 44 
CXCR4 production. Inhibition of CXCR4 activity altered the homing of quiescent tumour cells to bone.  45 
Conclusions: Mitotic dormancy is a unique phenotype that facilitates tumour cell colonization of the 46 
skeleton in prostate cancer.  47 
 48 
 49 
Abbreviations: CXCR4: C-X-C chemokine receptor type 4 50 
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Introduction  54 
Although prostatectomy is a successful treatment for prostate cancer that appears to be organ confined, in 55 
a significant number of patients the disease progresses, primarily by metastasis to the skeleton. In some 56 
cases this occurs many years after removal of the primary cancer so that it is clear that trafficking of tumor 57 
cells in/out of the bone microenvironment occurs at an early stage in the disease in some patients. It is also 58 
likely that this continues throughout the disease and is a major driver of disease progression.  59 
 60 
Recent studies have suggested that prostate cancers contain stem cell-like populations (1-9) and these may 61 
contribute to tumor heterogeneity and their adaptability. Others have suggested disseminating prostate 62 
FDQFHUFHOOVORFDWHWRµQLFKHV¶ZLWKLQWKHERne marrow, normally occupied by haematopoietic stem cells 63 
(HSCs) (10). However, the phenotype of the metastasis initiating population remains elusive, although it is 64 
believed that metastasizing cells will be mitotically quiescent. In this state they could survive in specific 65 
metastatic niches and their lack of proliferation would allow them to remain undetected for extended 66 
periods of time and confer resistance to anti-proliferative agents. 67 
 68 
We have studied several human prostate cancer cell lines in vitro to determine if they contain 69 
subpopulations that are mitotically quiescent with metastasis initiating potential. The cell lines were stained 70 
with vital lipophilic fluorescent dyes and followed in culture for several weeks. These dyes are very bright 71 
and importantly, are lost as cells divide, allowing non-dividing/slowly dividing cells, referred to here as 72 
quiescent, to be identified and distinguished from proliferating cells (11). Using this method we have 73 
isolated and characterized a low frequency, quiescent population from all cell lines. These cells or 74 
equivalent numbers of rapidly dividing cells were injected into the circulation of athymic mice and tumour 75 
growth assessed using bioluminescent in vivo imaging and post-mortem histology/2-photon microscopy. 76 
We assessed the relative capacities of these populations to form skeletal tumours in these animals. We have 77 
also presented a gene expression profile for quiescent cells. 78 
 79 
Methods  80 
Cell lines 81 
The PC3 prostate cancer cell line (ATCC) was stably transfected with a firefly luciferase gene luc2 82 
(pGL4.51 [luc2/CMV/Neo] vector, Promega) using a Gene PulserTM electroporator (Bio-Rad) (denoted 83 
PC3-NW1) and transfected with Amaxa pmaxGFP vector (Lonza) (PC3-GFP). LNCaP were purchased 84 
from ATCC (ATCC) and the C4 2B4 strain supplied by the University of Bern (Switzerland). All cell lines 85 
were maintained in 'XOEHFFR¶V0RGLILHG(DJOH¶V0HGLXP*LEFR/LIH7HFKQRORJLHVsupplemented with 86 
 4 
antibiotics and foetal bovine serum (Sigma Aldrich). All cell lines were genetically profiled by Stem Elite 87 
ID system (Promega) that confirmed their identity (18/18 STRs). 88 
 89 
Mitotically quiescent cells in vitro 90 
Defining the quiescent population in vitro 91 
Prostate cancer cells were stained in suspension ZLWKȝ0OLSRSKLOLFFDUERF\DQLQHG\H9\EUDQW'L' (Life 92 
Technologies) according to the manufacturers instructions. The proportion of cells retaining the dye 93 
with/without a 3hr pretreatment of 5µg/mL Mitomycin C (Sigma Aldrich) were analyzed by FACS (Calibur 94 
, BD Biosciences, Oxford, UK). Cells were imaged using a Leica DMI 4000B microscope (Leica 95 
Microsystems GmbH). The effect of lipophilic dyes on cell proliferation was determined by quantifying 96 
cell number up to 12 days in culture to determine the cell cycle phase of the quiescent population. DiD 97 
labeled PC3-NW1 cells were seeded at 6000/cm2 into a Permanox® Lab-Tek® Chamber Slide System 98 
(Thermo Scientific) and subcultured for 14 days. Mouse anti-human Ki-67 antibody (BD Bioscience) was 99 
then used to identify the growing cells according to the manufactureU¶VSURWRFRO7KHIUDFWLRQRI.L-67 100 
positive (Ki-67+) to negative (Ki-67-) cells were analyzed using the FACS Calibur flow cytometer and 101 
compared between the DiD positive (DiD+) and negative (DiD-) populations. 102 
 103 
TaqMan® Custom Array  104 
Mitotically quiescent and rapidly dividing cells were isolated on day 14 by FACS and total RNA extracted 105 
XVLQJWKH5HOLD3UHS51$&HOO0LQLSUHS6\VWHP3URPHJDF'1$ZDVV\QWKHVL]HGXVLQJ6XSHU6FULSW106 
III reverse trancriptase (Invitrogen, Life technologies) with a 1:1 mix of Oligo(dT) 15 and Random primers 107 
(Promega) and samples analyzed using a 96 gene TaqMan® low density array (Applied Biosystems) with 108 
an Applied Biosystems 7900HT Real-Time PCR system (Applied Biosystems) (50oC, 2min, 94.5oC, 10 109 
min, 97.0oC, 30 s, 59.7oC, 1 min, repeated x40), covering markers of stem cells, HSC niche components, 110 
epithelial to mesenchymal transition (EMT), extracellular matrix (ECM) and osteomimicry (complete list 111 
in Supplementary tables 1 and 2). Data was analysed using the Applied Biosystems SDS 2.3 software. 112 
Quantification of the target cDNAs in all samples was normalized to the endogenous control gene: GAPDH 113 
¨&7   &7target ± CTGAPDH). The difference in expression for each target cDNA between the between 114 
quiescent/non-qXLHVFHQWFHOOVZDVH[SUHVVHGDV¨¨&7¨¨&7 ¨&7quiescent - ¨&7non-quiescent). The relative 115 
H[SUHVVLRQOHYHOVIROGFKDQJHVZHUHWKHFDOFXODWHGXVLQJWRWKHSRZHURIWKH¨¨&7-¨¨CT), a two-fold 116 
expression change between cell types was deemed significant (Supplementary table 2).   117 
 118 
Immunofluorescence staining 119 
 5 
DiD labeled prostate cancer cells were subcultured for 14 days and cytospun onto slides. The cells were 120 
formalin fixed and stained with anti-human CXCR4 phycoerythrin conjugated monoclonal antibody (Clone 121 
12G5) or mouse IgG2A isotype control (R&D Systems) (1h, 20oC). For intracellular staining of matrix 122 
metalloproteinase-3 (MMP3) (using mouse monoclonal anti-MMP3 antibody) and follistatin (using mouse 123 
monoclonal anti-follistatin antibody) (Abcam, Cambridge, UK), the formalin fixed cells were permeablised 124 
first in 0.5 % tween diluted in PBS (PBST) and incubated with primary antibodies or isotype controls 125 
overnight at 4oC, followed by 30 minutes incubation with Goat anti-mouse IgG secondary antibody (Alexa 126 
Fluor® 488)(Abcam). All samples were then counterstained with 4',6-Diamidino-2-phenylindole, 127 
dihydrochloride (DAPI)  and imaged with a Leica AF6000 time lapse microscope (Leica Microsystems). 128 
The intensity of the immunofluorescence was then quantified with ImageJ software and compared between 129 
DiD+ and DiD- populations. 130 
 131 
Mitotically quiescent cells in vivo 132 
Mice 133 
Male BALB/c nude immunocompromised mice (Charles River) were used and all procedures complied 134 
with the UK Animals (Scientific Procedures) Act 1986 (PPL 40/3462). 135 
 136 
Intracardiac injection of tumor cells 137 
PC3-1: FHOOV ZHUH VWDLQHG ZLWK ȝ0 'L' DQG VLQJOH-cell suspensions of 1×105 DiD labeled PC-3 138 
FHOOVȝ/3%6ZHUHLQMHFWHGLQWo the left cardiac ventricle (intracardiac (i.c.) injection) of 6-week-old 139 
male BALB/c nude mice. Tumor growth was monitored for 6 weeks post injection using in vivo imaging 140 
systems (IVIS Caliper Life Sciences for detection of PC3-NW1 and the Illumatool Lighting System 141 
(LightTools Research) for detection of PC3-GFP). Cohorts of animals (n>6/group) were euthanized at 142 
different times post injection. DiD labeled LNCaP and C4 2B4 cells were also injected (i.c.) into 6-week-143 
old male BALB/c nude mice and animals were euthanized at 7 days post injection to confirm the presence 144 
of quiescent tumour cells in bone microenvironment.  145 
 146 
Multiphoton (2-Photon) microscopy 147 
Dissected tibias were snap-frozen in liquid nitrogen, embedded in Cryo-M-Bed compound and trimmed 148 
longitudinally to expose bone marrow area using a cryostat (Bright Instrument Co. Ltd). A stack area of 149 
ȝP[ȝPEHORZWKHJURZWKSODWHZLWKȝPLQGHSWKZDVLPDJHG=HLVV/601/2WZR-150 
photon microscope Carl Zeiss) and reconstructed with the LSM software 4.2 (Carl Zeiss Microscopy Ltd, 151 
Cambridge, UK) as previously described (12). A 633nm and 543nm HeNe laser was used to detect DiD 152 
and CM-DiI cells respectively. The bone and PC3-GFP cells were detected using the 900nm Chameleon 153 
 6 
multiphoton laser (Coherent, Santa Clara, CA.). The quantitative data; tumor cell number, size and distance 154 
from cell centroid to bone surface, were then analyzed by Volocity 3D Image Analysis software 6.01 155 
(PerkinElmer). 156 
 157 
Disruption the CXCR4 signalling in vivo 158 
DiD labeled 1×105 PC3-NW1 cells were i.c injected into 6-week-old male BALB/c nude mice. Seven days 159 
post injection, animals were subject to 5 days of treatment with CXCR4 inhibitor AMD3100 (5mg/kg, daily 160 
intrperitoneal injection)(Sigma Aldrich Co. Ltd, Poole, UK) or with PBS control (Figure 3D). Animals 161 
were then euthanized and the presence of DiD labelled tumour cells were examined and quantified using 162 
two-photon microscopy in tibias ex vivo.  163 
 164 
Comparison of the tumor forming ability of the quiescent and non-quiescent subpopulations. 165 
PC3-NW1 cells were stained ZLWKȝ0'L'subcultured and maintained at a density of at least 5x105 166 
cells/cm2 for 14 days. The DiD positive (DiD+) quiescent and negative (DiD-) fast growing subpopulations 167 
sorted by FACS (Aria cell sorter BD Biosciences, Oxford, UK). DiD+ quiescent cells were injected (i.c.) 168 
into 6-week-old male BALB/c nude mice (5x103 cells/mouse, n=15). DiD- non-quiescent cells were re-169 
stained with another lipophilic dye CellTracker, CM-DiI (Life Technologies) before injection (i.c) into age-170 
matched mice at two different concentrations (5x103 cells/mouse, n=15 and 1x105 cells/mouse, n=10), to 171 
allow tracking by 2-photon microscopy. A control, unsorted population of PC3-NW1 cells was passed 172 
through the FACS-Aria and 1×105 of these cells labeled with DiD and injected (i.c. n=10). Tumor growth 173 
was monitored up to 6 weeks post injection (IVIS) and the tumour burden was evaluated using the Living 174 
Imaging® In Vivo Imaging software (PerkinElmer Inc. Massachusetts, USA) based on photon radiance. 175 
The presence of DiD+/CM-Dil+ cells was also determined in tibias using 2-Photon microscopy post-176 
mortem.  177 
 178 
Statistical analysis 179 
$OOGDWDDUHH[SUHVVHGDVPHDQ6(06WDWLVWLFDOVLJQLILFDQFHZDVWHVWHGIRUXVLQJDQXQSDLUHG6WXGHQW¶V180 
t-WHVWZLWKRUZLWKRXW:HOVK¶VFRUUHFWLon or one-way ANOVA with post hoc Tukey test as appropriate using 181 
the Prism 6 software (GraphPad). P< 0.05 was considered to be significant. 182 
 183 
 184 
Results: 185 
Prostate cancer cell lines contain mitotically quiescent cell populations at low frequencies. 186 
 7 
PC3-NW1, LNCap and C4 2B4 cells were stained with DiD and followed for up to 3 weeks by flow 187 
cytometry. The proportion of cells labeled with DiD (% DiD+ve) did not change during the first 3 days, 188 
but rapidly declined to a steady level of dye retention by day 14. At this and later time points, a dye retentive 189 
population was present at a low frequency (<2%) (Figure 1 A, B, C). To test whether loss of dye was a 190 
result of proliferation (Figure 1A), cell division was inhibited in some cultures by treatment with Mitomycin 191 
C. This resulted in dye retention in a high percentage of cells. Cell proliferation under standard conditions 192 
was unaffected by DiD treatment (Figure 1D).  193 
 194 
To test the viability and proliferative potential of quiescent cells, cells that had retained DiD for 14 days in 195 
standard cultures were isolated by FACS and re-cultured at clonal density. The cells attached to dishes 196 
within 24h and remained as single cells for 3-5 days. After this time cells started to form colonies in which 197 
dye was sequentially lost in most but not all cells. (Figure 1E). This suggests that DiD retaining populations 198 
isolated by FACS remained viable and after a short delay, regained the ability to divide when cultured at 199 
low density. The retention of dye by some cells and its loss in most (Figure 1E, Day 10) may suggest some 200 
asymmetry in proliferation with some cells remaining relatively quiescent. 201 
 202 
When DiD retaining cells and proliferating cells were separated by FACS, dye retaining cells showed 203 
heterogeneity in proliferative marker Ki67 with both negative and positive staining within the population. 204 
However, the percentage of cells that were Ki67 positive were significantly lower in the DiD retaining 205 
population than in the proliferating cells (Figure 1 F,G).  206 
 207 
Mitotically quiescent populations have a distinctive gene expression profile 208 
 The Taqman custom arrays defined clear and significant differences in the genes expressed by quiescent 209 
(dye retaining) and non-quiescent populations isolated by FACS. In particular, type 1 collagen, CXCR4, 210 
fibronectin, follistatin, matrilin 2, MMP 2 and 3, prostate stem cell antigen, TMPRSS2, tenascin 3 and 211 
vitronectin were expressed at >2.5 fold higher levels in the quiescent population compared to the non-212 
quiescent cells. Of the other potential HSC niche components (13), the expression of Tie2 and JAG1 were 213 
raised but not significantly in the quiescent cells (Figure 2A, Supplementary data table 1). The expression 214 
of melanoma cell adhesion molecule (MCAM, CD146) and nestin were significantly lower in quiescent 215 
compared to the non-quiescent cells. While the quiescent cells expressed putative prostate stem cell 216 
markers, CD44, and integrins , there were no significant differences between expression levels in 217 
these cells compared to the proliferating population (Figure 2B). Expression of a further prostate stem cell 218 
marker, CD133, was very low in both populations (CT<35 cycles).  219 
 220 
 8 
The presence of protein encoded by 3 genes that were differentially expressed between DiD retaining and 221 
proliferating cells in the low density arrays, CXCR4, follistatin and MMP3 was assessed by 222 
immunofluoresecent staining of cytospin preparations from mixed cultures (Figure 2 C). Comparisons from 223 
multiple experiments showed that DiD positive cells expressed high levels of CXCR4 staining. However, 224 
there were no correlations between the presence of the other antigens and the transcript levels of the genes 225 
encoding these proteins or any associations with the quiescent phenotype Figure 2 C, D, E, F).    226 
 227 
Inhibition of CXCR4 alters the association of tumour cells with bone surfaces 228 
We were able to track tumour cells in vivo by pre-staining populations with DiD and examining tibias post-229 
mortem, by 2-photon microscopy. Animals injected with all three prostate cancer cell lines showed DiD 230 
labeled cells present in bone, signals that were absent from naïve mice (Figure 3A). Cells arrived in the 231 
tibia within 24h, accumulated during the first week and then declined slowly over the following weeks 232 
(Figure 3B). However, DiD +ve quiescent cells were still detectable in bone at 6 weeks. Tumour growth 233 
was monitored by bioluminescence as PC3-NW1 cells expressed luciferase. Growing lesions were 234 
generally detected after 3-4 weeks post-injection. The positions of tumour cells relative to bone were 235 
mapped and were shown to be in close proximity to bone (within 40236 
significant increase in the distance from bone structures with time (Figure 3C). 237 
   238 
To test the functional involvement of CXCR4 signaling in the retention of tumour cells within bone, cohorts 239 
of animals were treated with an agent that interferes with CXCR4 signaling (AMD3100) one week after 240 
injection with tumour cells (schematic: Figure 3D). This resulted in a significant shift in the positioning of 241 
tumour cells relative to bone surfaces (Figure 3E). There was no significant reduction in the total number 242 
of tumour cells detected within bone (Figure 3F), suggesting that tumour cells were not mobilized back 243 
into the circulation by this treatment. 244 
 245 
The mitotically quiescent phenotype in vitro is more tumorigenic in vivo than proliferating cells. 246 
We tested the hypothesis that the quiescent population, present in vitro was more tumorogenic in vivo. To 247 
do this, 5x105 mitotically quiescent (DiD+) or proliferating (DiD- on sorting, restained with CM-Dil so 248 
they could be tracked in vivo were injected (i.c.) into 6-week old animals to evaluate their tumourogenecity 249 
(Figure 4A). Animals were culled between 6-10 weeks post-injection of tumor cells, depending on severity 250 
of tumor burden. At this stage, both DiD+ and CM-Dil+ cells (sorted as DiD-) were present as single cells 251 
within the tibias examined by 2-photon microscopy using channels that discriminated DiD/CM-DiI labeled 252 
cells (Figure 4B). There were no DiD labeled cells detected amongst those labeled with CM-Dil. Neither 253 
the FACS sorting nor CM-DiI staining affected the tumourogenicity of PC3-NW1 as injection of 105 254 
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unsorted cells or sorted CM-DiI restained  cells produced high frequencies of growing tumours in skeleton 255 
(>80%) as in previous studies. This confirms that dye staining and FACS treatment did not affect tumour 256 
formation rates.  257 
 258 
Injection of 5x103 DiD- cells formed skeletal lesions in only 15% of animals, with no long bone lesions. 259 
Animals Injected with 5x103 DiD+ cells produced tumours in 55-60% of animals and tumors were observed 260 
in long bone tumors at week 6 post injection via the IVIS system and further anatomical confirmation post 261 
mortem (Figure 4C). Analyzed using the Living Imaging® In Vivo Imaging software, both the number of 262 
tumours in bone per mouse and the total bone tumour burden (photon radiance) of each mouse, were both 263 
statistically significantly higher in the group of mice injected with DiD+ cells (Figure 4D, 4E), further 264 
confirming the higher tumourogenicity of quiescent cells in skeleton.  Interestingly, there were no tumours 265 
present in non-skeletal sites in animals injected with cells that retained DiD for 14 days in cell culture while 266 
soft tissue tumours were seen in those that were injected with DiD ±ve sorted populations.  267 
268 
 10 
 269 
Discussion 270 
Two key findings have been demonstrated in these studies. Firstly we have shown that the widely used 271 
human prostate cancer cell lines PC3 and LNCaP and its variant C4 2B4 contain populations of cells that 272 
are slow growing/quiescent but not specifically stem like.  These cells are present in cultures where the 273 
majority population grows rapidly under standard conditions. Secondly, when this population was isolated 274 
from PC3-NW1 cells, it was able to form skeletal tumors more frequently than the more, rapidly dividing 275 
population, when injected into immunosuppressed animals. Others have recently used this technology to 276 
identify slow-growing cell populations in the PC3 cell line (14) but have not characterized separate cell 277 
populations as we have done here. 278 
 279 
We compared gene expression profiles of quiescent and proliferating populations using a low density array 280 
technology. The quiescent population in vitro expressed higher levels of CXCR4 and contained higher 281 
levels of this protein, measured by immunofluorescence, than non-quiescent cells. CXCR4 has been 282 
implicated in PC3 cell migration (10) and is required for the quiescence of HSC (15). The present study 283 
has identified CXCR4 as a marker of quiescent cells in a population with increased ability to form tumors 284 
in animals. Disruption of CXCR4 signaling using its antagonist AMD3100 did suggest that cells were 285 
induced to move away from bone surfaces and potentially away from osteoblast lineage cells a known 286 
source of the ligand SDF1 (CXCL12). This implies involvement of this signaling system in the homing 287 
process as suggested by others using these models (10)  where this treatment was shown to result in tumour 288 
cells re-entering the circulation. We did not see any reduction of tumour numbers in bone in our study that 289 
would have been indicative of remobilization of tumor cells to the circulation nor did we see an increase in 290 
circulating tumor cells in treated animals.  291 
 292 
While the expression of other genes in the selected arrays were increased, this did not appear to be reflected 293 
in increases in specific protein levels, apart from CXCR4.  There may be a number of reasons for this. 294 
Firstly, there may be genuinely no increased protein production associated with the elevated transcript 295 
levels observed. Alternatively, we may not have chosen the correct time window to observe increased 296 
protein levels or the assays were not sensitive enough to detect differences. However, the relationship 297 
between elevated expression of some of the other genes and cell migration/metastasis may be still worth 298 
considering. Of the other genes that were significantly upregulated as measured by QRT-PCR in the 299 
quiescent cell population, MMP3 is linked to the expression of CXCR4. This protease has been shown to 300 
be elevated in the serum of patients with metastatic prostate cancer (16) and its inhibition by treatment of 301 
animals with TIMP3, suppressed the formation of PC3 tumors (17). Others have shown that MMP3 302 
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expression is induced by CXCR4 signaling (18). MMP2 has been shown to be present in patient bone 303 
biopsies and in PC3 xenografts where it has been shown to induce recruitment of osteoclasts/participate in 304 
the formation of lytic bone disease (19)305 
integrin increased MMP2 production by PC3 cells and promoted osteolytic activity in vivo (20). The 306 
quiescent cells. 307 
Fibronectin is induced in EMT and has been associated with metastatic phenotype in breast cancer (21) as 308 
well as in prostate cancer cells (22) where overexpression of miR200b inhibited EMT, metastasis and 309 
downregulated fibronectin expression. Vitronectin has been associated with metastasis in breast cancer 310 
where binding of DVE3 integrin facilitated invasion under hypoxic conditions (23). Associations of 311 
vitronectin with this integrin have also been implicated as a driver of adhesion and invasion in prostate 312 
cancer (24). The present study would suggest that autologous production of ECM glycoproteins is a part of 313 
the quiescent, metastasis initiating phenotype. Similarly, tenascin C, which is produced by PC3 cells and 314 
expression elevated in the quiescent cells in our study, has been variably linked to reactive stroma in 315 
prostate cancer progression (25).  316 
 317 
The present study suggested that the quiescent population in the PC3-NW1 cell line did not specifically 318 
share the full putative prostate stem cell phenotype (1). In particular, the quiescent cells did not express 319 
E1 and CD44. However there were no significant 320 
differences in the levels of expression of these markers between quiescent and non-quiescent cells. In 321 
contrast the expression of PSCA was elevated in the quiescent population. This protein is highly expressed 322 
in prostate cancer compared to normal tissues and has been associated with tumor progression (26, 27). We 323 
conclude that while the quiescent population carries some stem cell markers these do not uniquely identify 324 
this population. It is quiescence itself that is specifically associated with increased capacity to form 325 
metastatic lesions in xenograft models. 326 
 327 
Taken together, the gene expression profiling data presented in this study suggests that the cells that are 328 
quiescent in vitro express higher levels of transcripts consistent with an invasive, metastatic phenotype. 329 
How and why this rare population is present or is generated in vitro remains to be discovered. 330 
 331 
The in vivo studies clearly demonstrated that the quiescent cells isolated from cell cultures were more 332 
tumourogenic in initiating tumours in bone than rapidly dividing populations. This suggests that the 333 
quiescent population contains higher numbers of cells capable of surviving in the circulation, homing to 334 
the bone marrow and eventually being activated to form growing lesions.  335 
 336 
 12 
Our studies suggest that mitotic quiescence, as defined by retention of the DiD dye for long periods, is in 337 
itself a marker for increased ability to form metastases in experimental animals. These cells carry some of 338 
the putative prostate cancer stem cell markers suggested by others but these are not exclusive to the 339 
quiescent phenotype. The consistently increased expression of CXCR4 in the quiescent population would 340 
enhance migration to bone for this cell type, which may, in part, provide an explanation for the increased 341 
capacity of these cells to generate lesions in bone. The presence of increased levels of this protein in tumour 342 
populations may be useful in predicting their capacity for migration and metastasis formation. In our 343 
previous studies, we have highlighted problems in detecting CXCR4 in prostate cancer tissues (7). In 344 
particular, we showed that the staining patterns reported were prone to artifact and that the overall frequency 345 
of CXCR4 staining was low in prostate tissues. To date, there have been no definitive, properly validated 346 
studies using primary prostate cancer tissue arrays with good clinical follow-up to test the hypothesis that 347 
the presence of CXCR4 in subpopulations of cells in these tissues predicts the presence of occult metastases 348 
in patients. Our studies and others (10) would suggest that this now needs to be given priority, especially 349 
where patients are being diagnosed with early stage disease and for whom prognosis is currently not clearly 350 
defined.  351 
 352 
In conclusion, our study is the first to show that mitotic quiescence identifies cells with the highest capacity 353 
to form bone metastases in prostate cancer models. This is counterintuitive in that it might be expected that 354 
rapidly growing populations would be more capable of forming lesions. However our studies show that the 355 
quiescent phenotype, with its consistent gene expression profile, in particular the production of CXCR4, 356 
allows cells to survive and home to bone where mitotic quiescence persists until proliferation is initiated. 357 
 358 
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 453 
Figure Legends: 454 
 455 
Figure 1: Defining the mitotically quiescent population in prostate cancer cell lines. 456 
 457 
A) Analysis of the retention of DiD labeling in cultures of PC3-NW1 cells in the presence and 458 
absence of mitomycin C for up to 3 weeks by flow cytometry. (n=3, **** p<0.0001, t test).  459 
B) A representative dot plot of flow cytometry gating shows distinct population of prostate cancer 460 
cells which maintain DiD labeling after 14 days of culture.  461 
C) Dye content (% DiD+ve) of PC3-NW1, LNCap and C42B4 stained with DiD were followed and 462 
analyzed for 14 days by flow cytometry. (n=3). 463 
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D) The effects of DiD labeling on proliferation over standard growth curves up to 12 days in culture. 464 
(n=3) 465 
E) Cells that retained DiD for 14 days were isolated by FACS and re-cultured at clonal density. 466 
Immunofluorescence microscopy was used to visualize DiD +ve cells at day 2, 6 and 10 post-467 
seeding. Scale bar = 50µm. 468 
F) Immunofluorescent image of mixed population with dye retaining cells (DiD+, Red) and 469 
proliferating cells (DiD-) were immunostained with mouse anti-human Ki-67 antibody (Green) 470 
and counterstained with DAPI (Blue). Scale bar = 50µm. 471 
G) Comparison of the percentage of Ki67 positivity between DiD+ and DiD- populations by flow 472 
cytometry analysis. (n=3, *** p<0.001, t test).  473 
 474 
Figure 2: Characterization of quiescent vs non-quiescent cells 475 
A) Fold differences in expression of connective tissue proteins, markers of EMT, and HSC niche 476 
molecules, compared between quiescent vs non-  to the 477 
housekeeping gene (GAPDH) measured by QRT-PCR in low-density arrays. (n=3, significant 478 
changes = fold differences >2 or < 0.5)  479 
B) Fold differences in expression of putative cancer stem cell markers, compared between quiescent 480 
vs non-quiescent cells. GAPDH) measured by QRT-481 
PCR in low-density arrays. (n=3, significant changes = fold differences >2 or < 0.5) ITGA2 : 482 
integrin a2, ITGB1: integrin b1  483 
C) Immunofluorescence staining showing that DiD labeled, quiescent PC3-NW1 cells (red) 484 
correlated with higher expression of CXCR4 protein (PE+, Green) but neither FST (Green) nor 485 
MMP3 (Green), following 14 days of culture after the initial DiD staining.  486 
D) The immunofluorescence staining intensity of CXCR4,  487 
E) FST, and  488 
F) MMP3 were quantified with ImageJ software and compared between DiD+ and DiD- populations. 489 
(Scale bar = 50µm. n=3, * p<0.05, ** p<0.01, paired t test) 490 
 491 
Figure 3. Disruption of CXCR4 interactions induces a shift in tumour cell position in bone. 492 
 493 
A) Two-photon scans of tibias from naïve mice and mice injected (intracardiac) with DiD labeled 494 
PC3-NW1, C4 2B4, and LNCaP cells, 7 days post injection. DiD labeled cells indicated (yellow 495 
arrows) 496 
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B) Frequency of DiD labeled tumor cells per mm3 bone marrow detected by 2-photon microscopy in 497 
tibias of a cohort of mice injected (intracardiac) with PC3-NW1 cells over a 6 weeks of time post 498 
injection (n > 6, ** p<0.01, one-way ANOVA with post Tukey test). 499 
C) The position of tumour cells relative to bone surfaces over time mapped using the Volocity 3D 500 
Image Analysis software. (n > 6). 501 
D) Schematic outline of the procedure used to inhibit CXCR4 and evaluate the association of tumour 502 
cells and bone: 6-week old athymic mice were injected (intracardiac) with DiD labeled PC3-NW1 503 
and daily treatment of CXCR4 antagonist (AMD3100) were started 7 days post injection for five 504 
consecutive days. The mice were then euthanized 24hr later for 2-photon microscopy analysis.  505 
E) The distance from tumour cells to the nearest bone surface, and 506 
F) The number of DiD labelled tumour cell per mm3 bone marrow were compared between the 507 
AMD3100 treated and control animals. (n=8, ** p<0.01, t test). 508 
 509 
Figure 4: Assessment of the growth and tumor initiating capacity of mitotically quiescent prostate 510 
cancer cells in vivo. 511 
 512 
A) Schematic outline of the procedure used to isolate and evaluate the tumorogenicity of mitotically 513 
quiescent and dividing cells in vivo: PC3-NW1 cells were stained with DiD and cultured 514 
continuously in standard medium for 14 days.  DiD retaining (DiD+) and non-retaining DiD- cells 515 
were FACS sorted and DiD- cells were restained with CM-Dil. Different populations were then 516 
injected intracardiac into athymic mice including mitotically quiescent (DiD+, 5x103 517 
cells/mouse), non-quiescent populations (DiD-, 5x103 cells/mouse) and the whole, mock-sorted 518 
population (1x105 cells/mouse). 519 
B) DiD (upper panel) or CM-DiI (DiD-, lower panel) labeled tumor cells were visualized in tibias by 520 
two-photon microscopy (arrows), 6 weeks post injection. 521 
C) The tumourogenecity in the skeleton especially in long bone were visualized by bioluminescence 522 
for 6 weeks post injection using IVIS system and compared between groups injected with DiD+ 523 
cells (n=15) and DiD- cells (n=15).  524 
D) The number of tumours per mouse, and  525 
E) Tumour burden (photon radiance) was analyzed and compared between the two groups using the 526 
Living Image software.  (n=15, * p<0.05, t test). 527 
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